Servier

    OverviewSuggest Edit

    Servier is a research-based group dedicated to health care. As the top-ranked French independent pharmaceutical laboratory, Servier reinvests more than 25% of its turnover in Research and Development. As a result, there are currently 29 new drug candidates under development in the following therapeutic areas: cardiology, oncology, metabolism, neuropsychiatry and rheumatology. With a presence on 5 continents and in 146 countries, Servier has put a total of 867 million drug treatments in the hands of patients in 2014. 92% of Servier's medicines are prescribed internationally.
    TypePrivate
    Founded1954
    HQSuresnes, FR
    Websiteservier.com
    Employee Ratings2.8

    Latest Updates

    Employees (est.) (Sep 2019)10,701

    Servier Office Locations

    Servier has offices in Suresnes, Nointot, Gidy, Croissy-sur-Seine and in 66 other locations
    Suresnes, FR (HQ)
    50 Rue Carnot
    Nointot, FR
    Baclair
    Sidi M'Hamed, DZ
    Algiers
    Minsk, BY
    303, vulica Miasnikova 70
    Varna, BG
    bul. "Tsar Osvoboditel" 14, ет.4София
    Laval, CA
    235 Boulevard Armand - Frappier
    Show all (83)

    Servier Financials and Metrics

    Summary Metrics

    Founding Date

    1954

    Servier Online and Social Media Presence

    Embed Graph

    Servier News and Updates

    Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients

    Mechelen, Belgium and Paris, France, 11 JUNE 2019, 07.00 CET - Servier and Galapagos NV (Euronext & NASDAQ: GLPG) completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule.

    Taiho Oncology and Servier Present LONSURF® (trifluridine and tipiracil) Data at the 2019 ASCO Annual Meeting

    PRINCETON, N.J., June 3, 2019 /PRNewswire/ -- Taiho Oncology, Inc. and Servier announced today clinical data with LONSURF® (trifluridine and tipiracil, TAS-102) in previously treated patients with metastatic gastric cancer (mGC), metastatic gastroesophageal junction adenocarcinoma (mGEJC) ...

    Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy

    SOUTH SAN FRANCISCO, Calif. and PARIS, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with its development partner Servier, an in…

    Taiho Oncology and Servier Present Data on LONSURF® (trifluridine/tipiracil) at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI)

    PRINCETON, N.J., Jan. 17, 2019 /PRNewswire/ -- Taiho Oncology, Inc. and Servier announced today that the safety and efficacy in patients with gastrectomy from the global Phase 3 TAGS trial evaluating LONSURF® in patients with previously treated metastatic gastric cancer (mGC) are...

    Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia

    SOUTH SAN FRANCISCO, Calif. and PARIS, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Servier, an independent international pharmaceutical com…
    Show more

    Servier Blogs

    Blood and Childhood Cancer Awareness Month

    […] L’article Blood and Childhood Cancer Awareness Month est apparu en premier sur Servier.

    Servier Vietnam committed to the prevention of cardiovascular diseases

    […] L’article Servier Vietnam committed to the prevention of cardiovascular diseases est apparu en premier sur Servier.

    Tianjin Facility in China Renews Local Partnership

    […] L’article Tianjin Facility in China Renews Local Partnership est apparu en premier sur Servier.

    Cardiology: Servier awards its Research Fellowship to a young European researcher

    […] L’article Cardiology: Servier awards its Research Fellowship to a young European researcher est apparu en premier sur Servier.

    Mécénat Servier launches its first joint initiatives!

    […] L’article Mécénat Servier launches its first joint initiatives! est apparu en premier sur Servier.

    The patient – the first victim of fake medicines

    […] L’article The patient – the first victim of fake medicines est apparu en premier sur Servier.
    Show more

    Servier Frequently Asked Questions

    • When was Servier founded?

      Servier was founded in 1954.

    • How many employees does Servier have?

      Servier has 10,701 employees.

    • Who are Servier competitors?

      Competitors of Servier include LGC Biosearch Technologies, Loxo Oncology and Keryx Biopharmaceuticals.

    • Where is Servier headquarters?

      Servier headquarters is located at 50 Rue Carnot, Suresnes.

    • Where are Servier offices?

      Servier has offices in Suresnes, Nointot, Gidy, Croissy-sur-Seine and in 66 other locations.

    • How many offices does Servier have?

      Servier has 83 offices.